0.6602
price up icon1.37%   0.0089
after-market Handel nachbörslich: .68 0.0198 +3.00%
loading
Schlusskurs vom Vortag:
$0.6513
Offen:
$0.652
24-Stunden-Volumen:
87,365
Relative Volume:
0.38
Marktkapitalisierung:
$59.97M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.15M
KGV:
-0.7255
EPS:
-0.91
Netto-Cashflow:
$-31.63M
1W Leistung:
+15.30%
1M Leistung:
-3.04%
6M Leistung:
-39.98%
1J Leistung:
-67.15%
1-Tages-Spanne:
Value
$0.6305
$0.6602
1-Wochen-Bereich:
Value
$0.56
$0.6602
52-Wochen-Spanne:
Value
$0.49
$2.75

Context Therapeutics Inc Stock (CNTX) Company Profile

Name
Firmenname
Context Therapeutics Inc
Name
Telefon
267-225-7416
Name
Adresse
2001 MARKET STREET, PHILADELPHIA
Name
Mitarbeiter
9
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-19
Name
Neueste SEC-Einreichungen
Name
CNTX's Discussions on Twitter

Vergleichen Sie CNTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CNTX
Context Therapeutics Inc
0.6602 59.97M 0 -30.15M -31.63M -0.91
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-21 Eingeleitet William Blair Outperform
2025-01-08 Eingeleitet JMP Securities Mkt Outperform
2024-11-25 Eingeleitet D. Boral Capital Buy
2024-05-16 Eingeleitet Piper Sandler Overweight

Context Therapeutics Inc Aktie (CNTX) Neueste Nachrichten

pulisher
Jun 13, 2025

Citadel Advisors LLC Makes New $31,000 Investment in Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World

Jun 13, 2025
pulisher
Jun 13, 2025

Millennium Management LLC Purchases 34,835 Shares of Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Context Therapeutics Approves Reverse Stock Split Amendment - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

Context Therapeutics Names Dr. Karen Chagin as Chief Medical Officer - MSN

Jun 12, 2025
pulisher
Jun 11, 2025

Co-Founder of Context Therapeutics Martin Lehr Buys 10% More Shares - simplywall.st

Jun 11, 2025
pulisher
Jun 10, 2025

Context Therapeutics Executives Increase Holdings - TradingView

Jun 10, 2025
pulisher
Jun 10, 2025

Context Therapeutics: Undervalued Cancer Fighter (NASDAQ:CNTX) - Seeking Alpha

Jun 10, 2025
pulisher
Jun 10, 2025

Jane Street Group LLC Makes New $29,000 Investment in Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World

Jun 10, 2025
pulisher
Jun 05, 2025

CNTXContext Therapeutics Reports First Quarter 2025 Operating and Financial Results - mx.advfn.com

Jun 05, 2025
pulisher
Jun 04, 2025

Northern Trust Corp Sells 58,946 Shares of Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World

Jun 04, 2025
pulisher
Jun 02, 2025

Context Therapeutics Inc. Advances CTIM-76 in Phase 1 Trial for Solid Tumors with Initial Data Expected in 2026 - Nasdaq

Jun 02, 2025
pulisher
Jun 02, 2025

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Context Therapeutics' Cancer Drug CTIM-76 Progresses in Phase 1 Trial: Key Updates from ASCO 2025 - Stock Titan

Jun 02, 2025
pulisher
May 30, 2025

Context Therapeutics names new CMO to advance T cell therapies By Investing.com - Investing.com South Africa

May 30, 2025
pulisher
May 29, 2025

Context Therapeutics (CNTX) Names New Chief Medical Officer | CN - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Context Therapeutics (CNTX) Names New Chief Medical Officer | CNTX Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Context Therapeutics names new CMO to advance T cell therapies - Investing.com

May 29, 2025
pulisher
May 29, 2025

Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer - GlobeNewswire

May 29, 2025
pulisher
May 29, 2025

Context Therapeutics Appoints Developer of First FDA-Approved Solid Tumor Cell Therapy as Chief Medical Officer - Stock Titan

May 29, 2025
pulisher
May 18, 2025

Context Therapeutics Grants Stock Options to New Hires as Part of Strategic Talent Growth - MSN

May 18, 2025
pulisher
May 17, 2025

Context Therapeutics Names Dr. Karen Smith as Interim Chief Medical Officer - MSN

May 17, 2025
pulisher
May 16, 2025

Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.40 Consensus Price Target from Analysts - Defense World

May 16, 2025
pulisher
May 15, 2025

Context Therapeutics Reports Q1 2025 Financial Results and Clinical Progress - MSN

May 15, 2025
pulisher
May 12, 2025

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 12, 2025
pulisher
May 12, 2025

William Blair Has Positive Outlook of CNTX FY2025 Earnings - Defense World

May 12, 2025
pulisher
May 12, 2025

Research Analysts Offer Predictions for CNTX Q2 Earnings - Defense World

May 12, 2025
pulisher
May 10, 2025

D. Boral Capital Reaffirms “Buy” Rating for Context Therapeutics (NASDAQ:CNTX) - Defense World

May 10, 2025
pulisher
May 09, 2025

UTR Therapeutics files IND application for UTRxM1-18 for c-MYC-driven cancers - BioWorld MedTech

May 09, 2025
pulisher
May 08, 2025

Context Therapeutics Showcases Promising CT-95 Data at AACR Annual Meeting - MSN

May 08, 2025
pulisher
May 08, 2025

Context Therapeutics (CNTX) Receives Continued 'Buy' Rating from Analyst | CNTX Stock News - GuruFocus

May 08, 2025
pulisher
May 07, 2025

FORE Biotherapeutics’ Plixorafenib Study to Be Highlighted at ASCO 2025 - MyChesCo

May 07, 2025
pulisher
May 07, 2025

CONTEXT THERAPEUTICS Earnings Results: $CNTX Reports Quarterly Earnings - Nasdaq

May 07, 2025
pulisher
May 07, 2025

Context Therapeutics Reports First Quarter 2025 Operating and Financial Results - GlobeNewswire

May 07, 2025
pulisher
May 06, 2025

Marshall Wace LLP Buys New Stake in Context Therapeutics Inc. (NASDAQ:CNTX) - The AM Reporter

May 06, 2025
pulisher
May 05, 2025

Context Therapeutics Appoints Karen Smith as Interim CMO - citybiz

May 05, 2025
pulisher
May 05, 2025

Context Therapeutics (CNTX) Names Karen Smith as Interim Chief Medical Officer | CNTX Stock News - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Context Therapeutics appoints new interim CMO - Investing.com

May 05, 2025
pulisher
May 05, 2025

Context Therapeutics appoints new interim CMO By Investing.com - Investing.com South Africa

May 05, 2025
pulisher
May 05, 2025

Context Therapeutics Announces Chief Medical Officer Transition - GlobeNewswire

May 05, 2025
pulisher
May 05, 2025

Context Therapeutics Inc Announces Executive Changes Effective May 10, 2025 - marketscreener.com

May 05, 2025
pulisher
May 05, 2025

Renaissance Technologies LLC Boosts Stock Holdings in Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World

May 05, 2025
pulisher
May 02, 2025

What is William Blair’s Estimate for CNTX Q2 Earnings? - Defense World

May 02, 2025
pulisher
May 02, 2025

Context Therapeutics Inc. (NASDAQ:CNTX) Stock Holdings Boosted by Geode Capital Management LLC - Defense World

May 02, 2025
pulisher
May 02, 2025

Context Therapeutics’ (CNTX) Outperform Rating Reiterated at William Blair - Defense World

May 02, 2025
pulisher
May 02, 2025

Context Therapeutics’ (CNTX) Buy Rating Reiterated at D. Boral Capital - Defense World

May 02, 2025

Finanzdaten der Context Therapeutics Inc-Aktie (CNTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Context Therapeutics Inc-Aktie (CNTX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Levit Alex C.
Chief Legal Officer, Corp. Sec
Jun 06 '25
Buy
0.58
20,000
11,520
29,000
Minai-Azary Jennifer Lynn
Chief Financial Officer
Jun 06 '25
Buy
0.64
40,010
25,486
80,010
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
Kapitalisierung:     |  Volumen (24h):